Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
  H. pylori e radication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial , with antibiotic resistance a contributing factor . D espite declining efficacy, physicians are still   prescribing these regimens   counter to ACG guidelines ,   which ...
View HTML
Toggle Summary RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
RHB-204 Phase 3 study in pulmonary NTM   infections is planned to be initiated in the coming weeks -- Orphan Drug Designation , along with RHB-204’s FDA QIDP priority designation, will extend U.S.   potential market exclusivity   to a total of 12 years TEL AVIV, Israel and RALEIGH, N.C. , Oct. ...
View HTML
Toggle Summary RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
         Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing   further strengthen s manufacturing capabilities and capacity ,   in preparation for potential emergency use applications  --        Enrollment in the g lobal Phase 2/3 COVID-19 study ...
View HTML
Toggle Summary RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
RedHill obtains Israel rights to Movantik ® from AstraZeneca ,   giv ing   RedHill global rights, excluding Europe and Canada -- Movantik approved for opioid-induced constipation   in Israel   under the brand name Mov e ntig ® -- RedHill to evaluate partnering opportunities for commercialization of ...
View HTML
Toggle Summary RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S.   Phase 2 study with opaganib in COVID-19  -- The U.S.   Phase 2 study   is 75% enrolled with data expected later this quarter -- In parallel, e nrollment ...
View HTML
Toggle Summary RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences
TEL AVIV, Israel and RALEIGH, N.C. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will present at the following virtual conferences in October: BIO Investor Forum Digital ( Oct. ...
View HTML
Toggle Summary Brazil Approves RedHill Biopharma’s Phase 2/3 COVID-19 Study with Opaganib
The ongoing   global Phase 2/3 study with orally-administered   opaganib in patients with severe COVID-19 is approved in Italy , the UK , Russia , Israel , Mexico and Brazil ; 16 clinical sites initiated globally to date -- In parallel , the   opaganib U.S. ...
View HTML
Toggle Summary RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events
TEL AVIV, Israel and RALEIGH, N.C. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that RedHill’s Chief Executive Officer, Dror Ben-Asher , will present at the Morgan Stanley Annual ...
View HTML
Toggle Summary RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study -- Opaganib is uniquely positioned as an orally-administered potential COVID-19 ...
View HTML
Toggle Summary RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia , and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with dual anti-inflammatory and anti-viral properties ...
View HTML